NASDAQ:AKCA Akcea Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akcea Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.14 0.00 (0.00 %) (As of 09/17/2020 12:00 AM ET) Add Compare Share Today's Range$18.13Now: $18.14▼$18.1650-Day Range$10.84MA: $13.71▼$18.2852-Week Range$8.00Now: $18.14▼$22.79Volume903,962 shsAverage Volume336,745 shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingAkcea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.72, Akcea Therapeutics has a forecasted upside of 52.8% from its current price of $18.14.Amount of Analyst CoverageAkcea Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAkcea Therapeutics has received 334 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkcea Therapeutics has received 354 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkcea Therapeutics has received 51.45% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote “Outperform” if you believe AKCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkcea Therapeutics does not currently pay a dividend.Dividend GrowthAkcea Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akcea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,288.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Akcea Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 19.27% of the stock of Akcea Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akcea Therapeutics are expected to decrease in the coming year, from ($1.66) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akcea Therapeutics is -33.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akcea Therapeutics is -33.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkcea Therapeutics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKCA Previous Symbol CUSIPN/A CIK1662524 Webwww.akceatx.com Phone617-207-0202Debt Debt-to-Equity RatioN/A Current Ratio12.17 Quick Ratio11.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$488.54 million Price / Sales3.77 Cash Flow$0.51 per share Price / Cash Flow35.50 Book Value$5.78 per share Price / Book3.14Profitability EPS (Most Recent Fiscal Year)$0.48 Net Income$40.77 million Net Margins-12.34% Return on Equity-8.94% Return on Assets-8.02%Miscellaneous Employees248 Outstanding Shares101,599,000Market Cap$1.84 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $18.14 0.00 (0.00 %) (As of 09/17/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AKCA News and Ratings via Email Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter. Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions How has Akcea Therapeutics' stock price been impacted by COVID-19? Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKCA stock has increased by 35.0% and is now trading at $18.14. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akcea Therapeutics. When is Akcea Therapeutics' next earnings date? Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Akcea Therapeutics. How were Akcea Therapeutics' earnings last quarter? Akcea Therapeutics Inc (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.14. The business earned $22.38 million during the quarter, compared to analyst estimates of $30.93 million. Akcea Therapeutics had a negative return on equity of 8.94% and a negative net margin of 12.34%. Akcea Therapeutics's revenue for the quarter was down 15.9% compared to the same quarter last year. During the same period last year, the company earned ($0.40) EPS. View Akcea Therapeutics' earnings history. What price target have analysts set for AKCA? 4 equities research analysts have issued 1-year price targets for Akcea Therapeutics' stock. Their forecasts range from $18.15 to $41.00. On average, they anticipate Akcea Therapeutics' stock price to reach $27.72 in the next year. This suggests a possible upside of 52.8% from the stock's current price. View analysts' price targets for Akcea Therapeutics. Who are some of Akcea Therapeutics' key competitors? Some companies that are related to Akcea Therapeutics include Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Myokardia (MYOK), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Legend Biotech (LEGN) and Blueprint Medicines (BPMC). View all competitors. What other stocks do shareholders of Akcea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), AMC Entertainment (AMC), Ciena (CIEN), Agile Therapeutics (AGRX), Apollo Global Management (APO) and Associated British Foods (ABF). Who are Akcea Therapeutics' key executives? Akcea Therapeutics' management team includes the following people: Ms. Paula Soteropoulos, CEO & Director (Age 51)Mr. Michael F. MacLean, Chief Financial Officer (Age 53)Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)Ms. Sarah Boyce, Pres & Director (Age 47)Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46) When did Akcea Therapeutics IPO? (AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager. What is Akcea Therapeutics' stock symbol? Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA." Who are Akcea Therapeutics' major shareholders? Akcea Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.44%), Vanguard Group Inc. (1.44%), Bellevue Group AG (1.44%), Point72 Asset Management L.P. (0.25%), Charles Schwab Investment Management Inc. (0.17%) and Alps Advisors Inc. (0.14%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics. Which institutional investors are selling Akcea Therapeutics stock? AKCA stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, FMR LLC, Marshall Wace LLP, Skandinaviska Enskilda Banken AB publ, Alps Advisors Inc., Amia Capital LLP, Nuveen Asset Management LLC, and Tudor Investment Corp Et Al. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Joshua F Patterson, and Kyle Jenne. View insider buying and selling activity for Akcea Therapeutics. Which institutional investors are buying Akcea Therapeutics stock? AKCA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., PDT Partners LLC, SG Americas Securities LLC, Prudential Financial Inc., Hancock Whitney Corp, Charles Schwab Investment Management Inc., and California Public Employees Retirement System. View insider buying and selling activity for Akcea Therapeutics. How do I buy shares of Akcea Therapeutics? Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akcea Therapeutics' stock price today? One share of AKCA stock can currently be purchased for approximately $18.14. How big of a company is Akcea Therapeutics? Akcea Therapeutics has a market capitalization of $1.84 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. What is Akcea Therapeutics' official website? The official website for Akcea Therapeutics is www.akceatx.com. How can I contact Akcea Therapeutics? Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
